Javelin 100 studien
Professor Powles er leder av Barts Cancer Center i London og han er også hovedutprøver for Javelin 100 UC–studien. I denne videoen går Professor Powles grundig gjennom dataene for Bavencio til bruk for urotelial kreft og hans synspunkter på behandlingen av de relevante pasientene
This presentation is based on the results published in Powles T, Park SH, Voog E, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med 2020;383:1218-30 at the October 21, 2019 cut-off date. A more recent analysis of overall survival data at a January 19, 2020 cut-off date has been included in the most recent update of the Bavencio SmPC. The updated results does not significantly differ from the published results and has no impact on the conclusions made in the presentation
Powles T, Park SH, Voog E, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med 2020;383:1218-30
